Advertisement

American Journal of Clinical Dermatology

, Volume 2, Issue 3, pp 135–141 | Cite as

Optimal Management of Acne to Prevent Scarring and Psychological Sequelae

  • Alison M. LaytonEmail author
Therapy in Practice

Abstract

Acne vulgaris is one of the most common inflammatory dermatoses and is seen in both the hospital setting and in general practice. Multiple factors are involved in the pathophysiology of acne, including: an alteration in the pattern of keratinization within the pilosebaceous follicles resulting in comedone formation; an increase in sebum production which is influenced by androgens; the proliferation of Propionibacterium acnes; and the production of perifollicular inflammation. Genetic and hormonal factors may also contribute to acne. Better understanding of the pathophysiology of the disease has led to the development of novel therapies which are directed at one or more of the implicated etiologic factors.

Systemic antibiotics for acne have been the mainstay of treatment for many years. The main cause for concern following the use of systemic antibiotics is the emergence of antibiotic-resistant strains of P. acnes. Concomitant use of non-antibiotic therapies such as benzoyl peroxide helps to decrease the occurrence of resistance and can be effective in the treatment of resistant and nonresistant propionibacterial strains. However, no one agent is able to eradicate resistant strains completely and as resistant strains correlate to poor clinical response to therapy, prescribing strategies are required to minimize the occurrence of resistance to P. acnes.

When assessing acne it is important to take an all embracing approach and to examine carefully for both the clinical and psychologic effects of the disease process. There are numerous forms of acne scarring and it is important to be aware of these as patients who are developing scarring merit early effective therapy. Some patients with acne will develop psychologic problems as a consequence of their condition. Even mild to moderate disease can be associated with significant depression and suicidal ideation and psychologic change does not necessarily correlate with disease severity. Acne scars themselves have been shown to produce significant psychopathology.

When initiating treatment it is important to consider the aims of therapy. Treatment should be aimed at achieving clearance of acne, prevention of scarring and, where necessary, relief from any psychologic stress resulting from the acne. Therapy should be commenced early in the disease process in order to prevent scarring and it is important to select appropriate therapies according to the clinical signs and psychologic disability. It is also important to ensure that the patient is able to comply with therapy and clear guidelines regarding treatment, possible adverse effects and realistic expectations should be provided.

Keywords

Acne Isotretinoin Benzoyl Peroxide Tretinoin Cyproterone Acetate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Eady E.A., Cove J.H., Cunliffe W.J. Erythromycin resistant propionibacteria in antibiotic treated acne patients: association with therapeutic failure. Br J Dermatol 1989; 121: 51–57PubMedCrossRefGoogle Scholar
  2. 2.
    Lleyden J.J. Therapy for acne vulgaris — review article. N Engl J Med 1997; 336: 1156–1162CrossRefGoogle Scholar
  3. 3.
    Leyden J.J., McGinley K.H., Cavalierie S., et al. Propionibacterium acnes resistance to antibiotics in acne patients. J Am Acad Dermatol 1983; 8: 41–45PubMedCrossRefGoogle Scholar
  4. 4.
    Farmery M.R., Jones C.E., Eady E.A., et al. In vitro activity of azeleic acid, benzoyl peroxide and zinc acetate against anti biotic-resistant propionibacteria from acne patients. J Dermatol Treat 1994; 5: 63–65CrossRefGoogle Scholar
  5. 5.
    Bojar R.A., Eady E.A., Jones C.E., et al. Inhibition of erythromycin resistant propionibacteria on the skin of acne patients by combining topical erythromycin with and without zinc. Br J Dermatol 1994; 130: 329–336PubMedCrossRefGoogle Scholar
  6. 6.
    Eady E.A., Bojar R.A., Jones C.E., et al. The effects of acne treatment with a combination of benzoyl peroxide and erythromycin on skin carriage of erythromycin resistant propionibacteria. Br J Dermatol 1996; 134: 107–113PubMedCrossRefGoogle Scholar
  7. 7.
    Coates P., Adams C.A., Cunliffe W. Does oral isotretinoin prevent propionibacterium acnes resistance? Dermatology 1997; 195 Suppl. 4–9PubMedCrossRefGoogle Scholar
  8. 8.
    Eady E.A., Jones C.E., Tipper, LE, et al. Antibiotic resistant propionibacteria in acne: need for policies to modify antibiotic usage. BMJ 1997; 306 (6877): 555–556CrossRefGoogle Scholar
  9. 9.
    Kirkup M.E., Dunill M.C.S. Management of acne prior to referral for isotretinoin therapy. Br J Dermatol 1999; 141 Suppl. 55: 53Google Scholar
  10. 10.
    Layton A.M., Seukeran D., Cunliffe W. Scarred for life? Dermatology 1997; 195 Suppl.: 15–21PubMedCrossRefGoogle Scholar
  11. 11.
    Sulzberger M.B., Zaidens S.H. Psychogenic factors in dermatologic disorders. Med Clin North Am 1948; 32: 669PubMedGoogle Scholar
  12. 12.
    Kenyon F.E. Psychosomatic aspects of acne. Br J Dermatol 1966; 78: 344–351CrossRefGoogle Scholar
  13. 13.
    Rubinov D.R. Reduced anxiety and depression in cystic acne patients after successful treatment with oral isotretinoin. J Am Acad Dermatol 1987; 17 (1): 25–32CrossRefGoogle Scholar
  14. 14.
    Shuster S., Fisher G.H., Harris E., et al. The effect of skin disease on self image. Br J Dermatol 1978; 99 Suppl. 16: 18–19PubMedCrossRefGoogle Scholar
  15. 15.
    van der Meeram H.L., van der Schoor W.W., van der Hib C.M. The psychological impact of severe acne. Cutis 1985; 36: 84–86Google Scholar
  16. 16.
    Gupta M.A., Gupta A.K. Depression and suicidal ideation in dermatology patients with acne, alopecia, areata, atopic dermatitis and psoriasis. Br J Dermatol 1998; 139: 846–850PubMedCrossRefGoogle Scholar
  17. 17.
    Seukeran D.C., Cunliffe W.J., Islam J., et al. The psychological impact of acne scarring. Br J Dermatol 1999; 144 Suppl. 55: 54Google Scholar
  18. 18.
    Brosden R.N., Goa R.L. Adapalene. A review of its pharmacological properties and clinical potential in the management of mild to moderate acne. Drugs 1997; 53 (5): 511–519CrossRefGoogle Scholar
  19. 19.
    Cunliffe W.J., Holland K.T. The effect of benzoyl peroxide on acne. Acta Dermatol Venereol 1981; 61: 267–269Google Scholar
  20. 20.
    Eady E.A., Cove J.H., Jones D.N., et al. Topical antibiotics for the treatment of acne vulgaris: a critical evaluation of the literature on their clinical benefit and comparative efficacy. J Dermatol Treat 1990; 1: 215–218CrossRefGoogle Scholar
  21. 21.
    Chu T. The role of topical retinoids in the treatment of acne. CME Dermatol Bull 2000; 2: 53–55Google Scholar
  22. 22.
    Eady E.A., Jones C.E., Tipper C.L. Antibiotic resistant propionibacteria in acne: need for policies to modify antibiotic usage. BMJ 1993; 306: 555–556PubMedCrossRefGoogle Scholar
  23. 23.
    Cunliffe W.J.. Propionibacteria acnes resistance and its clinical relevance. J Dermatol Treat 1995; 6 (Suppl. 1): 53–54Google Scholar
  24. 24.
    Greenwood K., Brommitt I.L., Burke B. Acne: double blind clinical and laboratory trial of tetracycline, oestrogen cyproterone acetate and combined treatment. BMJ 1985; 291: 1231–1235PubMedCrossRefGoogle Scholar
  25. 25.
    Hammerstein J., Meckier J., Leo-Rossburg I., et al. Use of cyproterone acetate (CPA) in the treatment of acne, hirsutism and virilism. J Steroid Biochem 1975; 6: 827–836PubMedCrossRefGoogle Scholar
  26. 26.
    Shaw J. Antiandrogen and hormonal treatment in acne. Dermatol Clin 1996; 14: 803–811PubMedCrossRefGoogle Scholar
  27. 27.
    Layton A.M., Hughes B.R., MacDonald-Hull S., et al. Seborrhoea — an indicator for clinical response in acne patients treated with antibiotics. Clin Exp Dermatol 1992; 17: 173–175PubMedCrossRefGoogle Scholar
  28. 28.
    Layton A.M., Knaggs H., Taylor J., et al. Isotretinoin for acne vulgaris — 10 years later: a safe and successful treatment. Br J Dermatol 1993; 129: 292–296PubMedCrossRefGoogle Scholar
  29. 29.
    Millard L. Adverse mood and behaviour change in young patients on systemic isotretinoin. Br J Dermatol 1999; 141 Suppl. 55: 16Google Scholar
  30. 30.
    Lee M.L., Cooper A. Isotretinoin: cost benefit study. Aust J Dermatol 1991; 32: 17–20CrossRefGoogle Scholar
  31. 31.
    Cunliffe W.J., van der Kerkhof P.C.M., Capcto R., et al. Roaccutane treatment guidelines: results of an international survey. Dermatology 1997; 194: 351–357PubMedCrossRefGoogle Scholar
  32. 32.
    Newton J.N., Mullan E., Klassen A., et al. The effectiveness of acne treatment: an assessment by patients of the outcome of therapy. Br J Dermatol 1997; 137 (4): 563–567PubMedCrossRefGoogle Scholar
  33. 33.
    Kellet S., Gawkrodger D.J.. The psychological and emotional impact of chronic acne and the effect of treatment with isotretinoin. Br J Dermatol 1998; 139 Suppl. 51: 56Google Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  1. 1.Harrogate District HospitalYorkshireEngland

Personalised recommendations